Table 2.
Base case results for France, all anthracycline doses
| Sarcoma patients | Haematological malignancy patients | |||
|---|---|---|---|---|
| Usual treatment | Usual treatment + dexrazoxane | Usual treatment | Usual treatment + dexrazoxane | |
| Clinical events | ||||
| Proportion with CHF (%) | 21.90 | 5.18 | 24.38 | 4.26 |
| Average age at CHF diagnosis (years) | 57.44 | 59.66 | 56.57 | 59.06 |
| Years of life with CHF | 4.90 | 1.07 | 5.45 | 0.88 |
| Number of CHF hospitalizations | 0.61 | 0.17 | 0.68 | 0.15 |
| Average age at death (years) | 68.93 | 69.00 | 67.42 | 67.55 |
| Cause of death (%) | ||||
| Death from cancer | 56.38 | 57.07 | 56.12 | 57.04 |
| Cardiac death | 5.42 | 4.12 | 5.69 | 3.95 |
| Death from infection or respiratory disease | 2.62 | 2.70 | 2.60 | 2.71 |
| Death from other disease | 28.06 | 28.49 | 28.10 | 28.69 |
| Violent death | 7.52 | 7.62 | 7.49 | 7.61 |
| Death from unknown cause | 0.00 | 0.00 | 0.00 | 0.00 |
| QALYs | ||||
| QALYs without cardiac disease | 18.379 | 19.593 | 18.528 | 20.099 |
| QALYs with ALVD | 1.044 | 0.681 | 1.094 | 0.500 |
| QALYs with CHF | 0.361 | 0.074 | 0.368 | 0.056 |
| Total QALYs | 19.783 | 20.349 | 19.990 | 20.654 |
| Total LY disc | 21.901 | 21.913 | 22.021 | 22.041 |
| Costs (€) | ||||
| Drug and administration costs | 7080.96 | 8123.61 | 7080.96 | 8123.61 |
| Heart failure costs | 757.48 | 199.24 | 806.93 | 140.74 |
| Death costs | 4261.18 | 4252.88 | 4198.35 | 4184.70 |
| Total costs | 12,099.62 | 12,575.73 | 12,086.25 | 12,449.05 |
| Incrementals | ||||
| QALYs | 0.565 | 0.665 | ||
| Costs (€) | 476.11 | 362.80 | ||
| ICER (€) | 894.55 | 545.87 | ||
ALVD asymptomatic left ventricular dysfunction, CHF congestive heart failure, ICER incremental cost effectiveness ratio, QALY quality-adjusted life years